KannaLife

KannaLife is a biopharmaceutical company that specializes in the research and development of cannabinoid therapeutics. The company is particularly known for its work in the field of neurodegenerative diseases, with a focus on hepatocellular carcinoma and chronic traumatic encephalopathy (CTE).

History

KannaLife was founded in 2010 with the aim of exploring the potential therapeutic uses of cannabinoids. The company was granted a license by the National Institutes of Health (NIH) to develop cannabinoid-based treatments for two types of brain damage: hepatic encephalopathy, which is caused by liver failure, and CTE, which is caused by repeated head trauma.

Research and Development

KannaLife's research is centered on the development of novel new drugs that can exploit the therapeutic potential of cannabinoids. The company's lead drug candidate, KLS-13019, is a cannabinoid-derived neuroprotective agent that is currently in preclinical development for the treatment of hepatic encephalopathy and CTE.

KannaLife's research has shown that KLS-13019 has the potential to reduce oxidative stress, inflammation, and cell death in the brain, all of which are implicated in the pathogenesis of hepatic encephalopathy and CTE. The company is currently conducting further preclinical studies to confirm these findings and to determine the optimal dosing regimen for KLS-13019.

Partnerships and Collaborations

KannaLife has established several strategic partnerships and collaborations to advance its research and development efforts. These include partnerships with academic institutions, such as the University of Pennsylvania and the Temple University School of Pharmacy, as well as collaborations with other biopharmaceutical companies.

Future Directions

KannaLife continues to explore the therapeutic potential of cannabinoids in the treatment of neurodegenerative diseases. The company's ongoing research and development efforts are focused on advancing KLS-13019 through preclinical development and into clinical trials.

See Also

• Cannabinoid
• Neurodegenerative diseases
• Hepatocellular carcinoma
• Chronic traumatic encephalopathy